Th17/Th1 biased immunity to the pneumococcal proteins PcsB, StkP and PsaA in adults of different age

Vaccine

Volumn 29, Issue 23, 2011, Pages 3982-3989

  Schmid, Petra ^a   Selak, Sanja ^b   Keller, Michael ^a   Luhan, Barbara ^a   Magyarics, Zoltan ^c   Seidel, Stefan ^b   Schlick, Petra ^b   Reinisch, Christoph ^b   Lingnau, Karen ^b   Nagy, Eszter ^c   Grubeck Loebenstein, Beatrix ^a  

^a ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

^b INTERCELL AG   (Austria)

^c Arsanis Inc   (Austria)

Author keywords

Elderly; Human cellular response; PcsB; Pneumococcus; PsaA; StkP; Th1; Th17

Indexed keywords

BACTERIAL PROTEIN; CYTOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 17 ANTIBODY; INTERLEUKIN 5; PNEUMOCOCCUS VACCINE; PROTEIN PSAA; PROTEIN STKP; PROTEINS PCSB; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DONOR; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNITY; NORMAL HUMAN; PRIORITY JOURNAL; TH1 CELL; TH17 CELL;

ADHESINS, BACTERIAL; ADULT; AGED; AGED, 80 AND OVER; AGING; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; HUMANS; LIPOPROTEINS; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; STREPTOCOCCUS PNEUMONIAE; TH1 CELLS; TH17 CELLS; VACCINATION; YOUNG ADULT;

EID: 79955666578     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.03.081     Document Type: Article

References (66)

1. Fedson D.S., Liss C. Precise answers to the wrong question: prospective clinical trials and the meta-analyses of pneumococcal vaccine in elderly and high-risk adults. Vaccine 2004, 22(February (8)):927-946.
2. Jackson L.A., Janoff E.N. Pneumococcal vaccination of elderly adults: new paradigms for protection. Clin Infect Dis 2008, 47(November (10)):1328-1338.
3. Dominguez A., Izquierdo C., Salleras L., Ruiz L., Sousa D., Bayas J.M., et al. Effectiveness of the pneumococcal polysaccharide vaccine in preventing pneumonia in the elderly. Eur Respir J 2010, 36(September (3)):608-614.
4. Vila-Corcoles A., Ochoa-Gondar O., Guzman J.A., Rodriguez-Blanco T., Salsench E., Fuentes C.M. Effectiveness of the 23-valent polysaccharide pneumococcal vaccine against invasive pneumococcal disease in people 60 years or older. BMC Infect Dis 2010, 10:73.
5. Black S., Shinefield H., Fireman B., Lewis E., Ray P., Hansen J.R., et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000, 19(March (3)):187-195.
6. Eskola J., Kilpi T., Palmu A., Jokinen J., Haapakoski J., Herva E., et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001, 344(February (6)):403-409.
7. Cutts F.T., Zaman S.M., Enwere G., Jaffar S., Levine O.S., Okoko J.B., et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet 2005, 365(March-April (9465)):1139-1146.
8. Goldblatt D., Southern J., Andrews N., Ashton L., Burbidge P., Woodgate S., et al. The immunogenicity of 7-valent pneumococcal conjugate vaccine vs. 23-valent polysaccharide vaccine in adults aged 50-80 years. Clin Infect Dis 2009, 49(November (9)):1318-1325.
9. Lottenbach K.R., Mink C.M., Barenkamp S.J., Anderson E.L., Homan S.M., Powers D.C. Age-associated differences in immunoglobulin G1 (IgG1) and IgG2 subclass antibodies to pneumococcal polysaccharides following vaccination. Infect Immun 1999, 67(September (9)):4935-4938.
10. Powers D.C., Anderson E.L., Lottenbach K., Mink C.M. Reactogenicity and immunogenicity of a protein-conjugated pneumococcal oligosaccharide vaccine in older adults. J Infect Dis 1996, 173(April (4)):1014-1018.
11. Musher D.M., Rueda A.M., Nahm M.H., Graviss E.A., Rodriguez-Barradas M.C. Initial and subsequent response to pneumococcal polysaccharide and protein-conjugate vaccines administered sequentially to adults who have recovered from pneumococcal pneumonia. J Infect Dis 2008, 198(October (7)):1019-1027.
12. Adamou J.E., Heinrichs J.H., Erwin A.L., Walsh W., Gayle T., Dormitzer M., et al. Identification and characterization of a novel family of pneumococcal proteins that are protective against sepsis. Infect Immun 2001, 69(February (2)):949-958.
13. Briles D.E., Ades E., Paton J.C., Sampson J.S., Carlone G.M., Huebner R.C., et al. Intranasal immunization of mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniae. Infect Immun 2000, 68(February (2)):796-800.
14. Daniels C.C., Coan P., King J., Hale J., Benton K.A., Briles D.E., et al. The proline-rich region of pneumococcal surface proteins A and C contains surface-accessible epitopes common to all pneumococci and elicits antibody-mediated protection against sepsis. Infect Immun 2010, 78(May (5)):2163-2172.
15. Ferreira D.M., Darrieux M., Silva D.A., Leite L.C., Ferreira J.M., Ho P.L., et al. Characterization of protective mucosal and systemic immune responses elicited by pneumococcal surface protein PspA and PspC nasal vaccines against a respiratory pneumococcal challenge in mice. Clin Vaccine Immunol 2009, 16(May (5)):636-645.
16. Hamel J., Charland N., Pineau I., Ouellet C., Rioux S., Martin D., et al. Prevention of pneumococcal disease in mice immunized with conserved surface-accessible proteins. Infect Immun 2004, 72(May (5)):2659-2670.
17. Ogunniyi A.D., Grabowicz M., Briles D.E., Cook J., Paton J.C. Development of a vaccine against invasive pneumococcal disease based on combinations of virulence proteins of Streptococcus pneumoniae. Infect Immun 2007, 75(January (1)):350-357.
18. Linder A., Hollingshead S., Janulczyk R., Christensson B., Akesson P. Human antibody response towards the pneumococcal surface proteins PspA and PspC during invasive pneumococcal infection. Vaccine 2007, 25(January (2)):341-345.
19. McCool T.L., Cate T.R., Moy G., Weiser J.N. The immune response to pneumococcal proteins during experimental human carriage. J Exp Med 2002, 195(February (3)):359-365.
20. Rapola S., Jantti V., Haikala R., Syrjanen R., Carlone G.M., Sampson J.S., et al. Natural development of antibodies to pneumococcal surface protein A, pneumococcal surface adhesin A, and pneumolysin in relation to pneumococcal carriage and acute otitis media. J Infect Dis 2000, 182(October (4)):1146-1152.
21. Virolainen A., Russell W., Crain M.J., Rapola S., Kayhty H., Briles D.E. Human antibodies to pneumococcal surface protein A in health and disease. Pediatr Infect Dis J 2000, 19(February (2)):134-138.
22. Simell B., Korkeila M., Pursiainen H., Kilpi T.M., Kayhty H. Pneumococcal carriage and otitis media induce salivary antibodies to pneumococcal surface adhesin a, pneumolysin, and pneumococcal surface protein a in children. J Infect Dis 2001, 183(March (6)):887-896.
23. Zhang Q., Choo S., Finn A. Immune responses to novel pneumococcal proteins pneumolysin, PspA, PsaA, and CbpA in adenoidal B cells from children. Infect Immun 2002, 70(October (10)):5363-5369.
24. Holmlund E., Simell B., Jaakkola T., Lahdenkari M., Hamel J., Brodeur B., et al. Serum antibodies to the pneumococcal surface proteins PhtB and PhtE in Finnish infants and adults. Pediatr Infect Dis J 2007, 26(May (5)):447-449.
25. Briles D.E., Hollingshead S.K., King J., Swift A., Braun P.A., Park M.K., et al. Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA. J Infect Dis 2000, 182(December (6)):1694-1701.
26. Barocchi M.A., Censini S., Rappuoli R. Vaccines in the era of genomics: the pneumococcal challenge. Vaccine 2007, 25(April (16)):2963-2973.
27. Tai S.S. Streptococcus pneumoniae protein vaccine candidates: properties, activities and animal studies. Crit Rev Microbiol 2006, 32(3):139-153.
28. Giefing C., Meinke A.L., Hanner M., Henics T., Bui M.D., Gelbmann D., et al. Discovery of a novel class of highly conserved vaccine antigens using genomic scale antigenic fingerprinting of pneumococcus with human antibodies. J Exp Med 2008, 205(January (1)):117-131.
29. Barendt S.M., Land A.D., Sham L.T., Ng W.L., Tsui H.C., Arnold R.J., et al. Influences of capsule on cell shape and chain formation of wild-type and PcsB mutants of serotype 2 Streptococcus pneumoniae. J Bacteriol 2009, 191(May (9)):3024-3040.
30. Ng W.L., Kazmierczak K.M., Winkler M.E. Defective cell wall synthesis in Streptococcus pneumoniae R6 depleted for the essential PcsB putative murein hydrolase or the VicR (YycF) response regulator. Mol Microbiol 2004, 53(August (4)):1161-1175.
31. Reinscheid D.J., Ehlert K., Chhatwal G.S., Eikmanns B.J. Functional analysis of a PcsB-deficient mutant of group B streptococcus. FEMS Microbiol Lett 2003, 221(April (1)):73-79.
32. Novakova L., Saskova L., Pallova P., Janecek J., Novotna J., Ulrych A., et al. Characterization of a eukaryotic type serine/threonine protein kinase and protein phosphatase of Streptococcus pneumoniae and identification of kinase substrates. FEBS J 2005, 272(March (5)):1243-1254.
33. Pallova P., Hercik K., Saskova L., Novakova L., Branny P. A eukaryotic-type serine/threonine protein kinase StkP of Streptococcus pneumoniae acts as a dimer in vivo. Biochem Biophys Res Commun 2007, 355(April (2)):526-530.
34. Saskova L., Novakova L., Basler M., Branny P. Eukaryotic-type serine/threonine protein kinase StkP is a global regulator of gene expression in Streptococcus pneumoniae. J Bacteriol 2007, 189(June (11)):4168-4179.
35. Giefing C., Jelencsics K.E., Gelbmann D., Senn B.M., Nagy E. The pneumococcal eukaryotic-type serine/threonine protein kinase StkP co-localizes with the cell division apparatus and interacts with FtsZ in vitro. Microbiology 2010, 156(Pt 6):1697-1707.
36. Palaniappan R., Singh S., Singh U.P., Sakthivel S.K., Ades E.W., Briles D.E., et al. Differential PsaA-, PspA-, PspC-, and PdB-specific immune responses in a mouse model of pneumococcal carriage. Infect Immun 2005, 73(February (2)):1006-1013.
37. Malley R., Trzcinski K., Srivastava A., Thompson C.M., Anderson P.W., Lipsitch M. CD4+ T cells mediate antibody-independent acquired immunity to pneumococcal colonization. Proc Natl Acad Sci USA 2005, 102(March (13)):4848-4853.
38. Trzcinski K., Thompson C.M., Srivastava A., Basset A., Malley R., Lipsitch M. Protection against nasopharyngeal colonization by Streptococcus pneumoniae is mediated by antigen-specific CD4+ T cells. Infect Immun 2008, 76(June (6)):2678-2684.
39. Lu Y.J., Gross J., Bogaert D., Finn A., Bagrade L., Zhang Q., et al. Interleukin-17A mediates acquired immunity to pneumococcal colonization. PLoS Pathog 2008, 4(9):e1000159.
40. Zhang Z., Clarke T.B., Weiser J.N. Cellular effectors mediating Th17-dependent clearance of pneumococcal colonization in mice. J Clin Invest 2009, 119(July (7)):1899-1909.
41. Basset A., Thompson C.M., Hollingshead S.K., Briles D.E., Ades E.W., Lipsitch M., et al. Antibody-independent CD4+ T-cell-dependent protection against pneumococcal colonization elicited by intranasal immunization with purified pneumococcal proteins. Infect Immun 2007, 75(November (11)):5460-5464.
42. Gibson K.L., Wu Y.C., Barnett Y., Duggan O., Vaughan R., Kondeatis E., et al. B-cell diversity decreases in old age and is correlated with poor health status. Aging Cell 2009, 8(February (1)):18-25.
43. Allman D., Miller J.P. B cell development and receptor diversity during aging. Curr Opin Immunol 2005, 17(October (5)):463-467.
44. Frasca D., Riley R.L., Blomberg B.B. Humoral immune response and B-cell functions including immunoglobulin class switch are downregulated in aged mice and humans. Semin Immunol 2005, 17(October (5)):378-384.
45. Howard W.A., Gibson K.L., Dunn-Walters D.K. Antibody quality in old age. Rejuvenation Res 2006, 9(Spring (1)):117-125.
46. Breitbart E., Wang X., Leka L.S., Dallal G.E., Meydani S.N., Stollar B.D. Altered memory B-cell homeostasis in human aging. J Gerontol A Biol Sci Med Sci 2002, 57(August (8)):B304-B311.
47. Bogaert D., De Groot R., Hermans P.W. Streptococcus pneumoniae colonization: the key to pneumococcal disease. Lancet Infect Dis 2004, 4(March (3)):144-154.
48. Garcia-Rodriguez J.A., Fresnadillo Martinez M.J. Dynamics of nasopharyngeal colonization by potential respiratory pathogens. J Antimicrob Chemother 2002, 50(December (Suppl S2)):59-73.
49. Mureithi M.W., Finn A., Ota M.O., Zhang Q., Davenport V., Mitchell T.J., et al. T cell memory response to pneumococcal protein antigens in an area of high pneumococcal carriage and disease. J Infect Dis 2009, 200(September (5)):783-793.
50. Zhang Q., Bagrade L., Bernatoniene J., Clarke E., Paton J.C., Mitchell T.J., et al. Low CD4T cell immunity to pneumolysin is associated with nasopharyngeal carriage of pneumococci in children. J Infect Dis 2007, 195(April (8)):1194-1202.
51. Zhang Q., Bernatoniene J., Bagrade L., Paton J.C., Mitchell T.J., Hammerschmidt S., et al. Regulation of production of mucosal antibody to pneumococcal protein antigens by T-cell-derived gamma interferon and interleukin-10 in children. Infect Immun 2006, 74(August (8)):4735-4743.
52. Ericsson M., Sandstrom G., Sjostedt A., Tarnvik A. Persistence of cell-mediated immunity and decline of humoral immunity to the intracellular bacterium Francisella tularensis 25 years after natural infection. J Infect Dis 1994, 170(July (1)):110-114.
53. Hainz U., Jenewein B., Asch E., Pfeiffer K.P., Berger P., Grubeck-Loebenstein B. Insufficient protection for healthy elderly adults by tetanus and TBE vaccines. Vaccine 2005, 23(May (25)):3232-3235.
54. McElhaney J.E., Xie D., Hager W.D., Barry M.B., Wang Y., Kleppinger A., et al. T cell responses are better correlates of vaccine protection in the elderly. J Immunol 2006, 176(May (10)):6333-6339.
55. Liu H., Rohowsky-Kochan C. Regulation of IL-17 in human CCR6+ effector memory T cells. J Immunol 2008, 180(June (12)):7948-7957.
56. Annunziato F., Cosmi L., Liotta F., Maggi E., Romagnani S. The phenotype of human Th17 cells and their precursors, the cytokines that mediate their differentiation and the role of Th17 cells in inflammation. Int Immunol 2008, 20(November (11)):1361-1368.
57. Acosta-Rodriguez E.V., Napolitani G., Lanzavecchia A., Sallusto F. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 2007, 8(September (9)):942-949.
58. De Martinis M., Franceschi C., Monti D., Ginaldi L. Inflammation markers predicting frailty and mortality in the elderly. Exp Mol Pathol 2006, 80(June (3)):219-227.
59. Ershler W.B., Keller E.T. Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. Annu Rev Med 2000, 51:245-270.
60. Franceschi C., Capri M., Monti D., Giunta S., Olivieri F., Sevini F., et al. Inflammaging and anti-inflammaging: a systemic perspective on aging and longevity emerged from studies in humans. Mech Ageing Dev 2007, 128(January (1)):92-105.
61. Richards L., Ferreira D.M., Miyaji E.N., Andrew P.W., Kadioglu A. The immunizing effect of pneumococcal nasopharyngeal colonization; protection against future colonization and fatal invasive disease. Immunobiology 2010, 215(April (4)):251-263.
62. Evans H.G., Suddason T., Jackson I., Taams L.S., Lord G.M. Optimal induction of T helper 17 cells in humans requires T cell receptor ligation in the context of Toll-like receptor-activated monocytes. Proc Natl Acad Sci USA 2007, 104(October (43)):17034-17039.
63. Malley R. Antibody and cell-mediated immunity to Streptococcus pneumoniae: implications for vaccine development. J Mol Med 2010, 88(February (2)):135-142.
64. Kaml M., Weiskirchner I., Keller M., Luft T., Hoster E., Hasford J., et al. Booster vaccination in the elderly: their success depends on the vaccine type applied earlier in life as well as on pre-vaccination antibody titers. Vaccine 2006, 24(November (47-48)):6808-6811.
65. Aspinall R., Del Giudice G., Effros R.B., Grubeck-Loebenstein B., Sambhara S. Challenges for vaccination in the elderly. Immun Ageing 2007, 4:9.
66. Grubeck-Loebenstein B., Della Bella S., Iorio A.M., Michel J.P., Pawelec G., Solana R. Immunosenescence and vaccine failure in the elderly. Aging Clin Exp Res 2009, 21(June (3)):201-209.